• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

无菌性脓肿综合征:一例患者使用英夫利昔单抗原研药和生物类似药并以不同间隔给药后病情缓解的病例报告

Aseptic abscess syndrome: a case report of a patient achieving remission with both infliximab originator and biosimilar administered at varied intervals.

作者信息

Ucci Federica Maria, Scrivo Rossana, Alessandri Cristiano, Conti Fabrizio, Priori Roberta

机构信息

Department of Clinical Internal, Anesthesiologic and Cardiovascular Sciences, Rheumatology Unit, Sapienza University of Rome, Rome, Italy.

Saint Camillus International University of Health Science, UniCamillus, Rome, Italy.

出版信息

Front Immunol. 2024 Dec 3;15:1454813. doi: 10.3389/fimmu.2024.1454813. eCollection 2024.

DOI:10.3389/fimmu.2024.1454813
PMID:39691706
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11649502/
Abstract

Aseptic abscesses syndrome is a rare but increasingly recognized disease that falls within the spectrum of autoinflammatory disorders. Here, we describe the case of a patient who presented with abdominal pain and fever, along with multiple abdominal and extra-abdominal abscesses, in the absence of underlying hematologic, autoimmune, infectious, or neoplastic conditions. Initially, the patient responded to glucocorticoids, but experienced several flares upon discontinuation, leading to the initiation of treatment with a TNFα inhibitor. After 5 years, an attempt to discontinue treatment resulted in a new flare of the disease. Remission was eventually achieved with a biosimilar TNFα inhibitor, albeit requiring shortened infusion intervals.

摘要

无菌性脓肿综合征是一种罕见但越来越被认识到的疾病,属于自身炎症性疾病范畴。在此,我们描述了一例患者,该患者出现腹痛和发热,伴有多个腹部和腹部外脓肿,且不存在潜在的血液学、自身免疫性、感染性或肿瘤性疾病。最初,患者对糖皮质激素有反应,但停药后经历了几次病情复发,导致开始使用肿瘤坏死因子α(TNFα)抑制剂进行治疗。5年后,尝试停药导致疾病再次发作。最终使用一种生物类似物TNFα抑制剂实现了缓解,尽管需要缩短输注间隔时间。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0fd4/11649502/ea8f0f4129a1/fimmu-15-1454813-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0fd4/11649502/d65540855774/fimmu-15-1454813-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0fd4/11649502/ee61a30ce198/fimmu-15-1454813-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0fd4/11649502/62719905e8b7/fimmu-15-1454813-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0fd4/11649502/ea8f0f4129a1/fimmu-15-1454813-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0fd4/11649502/d65540855774/fimmu-15-1454813-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0fd4/11649502/ee61a30ce198/fimmu-15-1454813-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0fd4/11649502/62719905e8b7/fimmu-15-1454813-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0fd4/11649502/ea8f0f4129a1/fimmu-15-1454813-g004.jpg

相似文献

1
Aseptic abscess syndrome: a case report of a patient achieving remission with both infliximab originator and biosimilar administered at varied intervals.无菌性脓肿综合征:一例患者使用英夫利昔单抗原研药和生物类似药并以不同间隔给药后病情缓解的病例报告
Front Immunol. 2024 Dec 3;15:1454813. doi: 10.3389/fimmu.2024.1454813. eCollection 2024.
2
Switching Australian patients with moderate to severe inflammatory bowel disease from originator to biosimilar infliximab: a multicentre, parallel cohort study.将澳大利亚中重度炎症性肠病患者的英夫利昔单抗原研药换成生物类似药:一项多中心平行队列研究。
Med J Aust. 2021 Feb;214(3):128-133. doi: 10.5694/mja2.50824. Epub 2020 Oct 17.
3
Serum concentrations after switching from originator infliximab to the biosimilar CT-P13 in patients with quiescent inflammatory bowel disease (SECURE): an open-label, multicentre, phase 4 non-inferiority trial.在炎症性肠病处于缓解期的患者中,由原研英夫利昔单抗转换为生物类似药 CT-P13 后的血清浓度(SECURE):一项开放标签、多中心、四期非劣效性试验。
Lancet Gastroenterol Hepatol. 2018 Jun;3(6):404-412. doi: 10.1016/S2468-1253(18)30082-7. Epub 2018 Mar 30.
4
Characteristics and outcomes of rheumatoid arthritis patients who started biosimilar infliximab.开始使用生物类似药英夫利昔单抗的类风湿关节炎患者的特征与结局
Rheumatol Int. 2017 Jun;37(6):1007-1014. doi: 10.1007/s00296-017-3663-z. Epub 2017 Feb 18.
5
Recurrence Rates of Inflammation after Switching from the Originator Infliximab to Biosimilar Infliximab-abda for Noninfectious Uveitis.非感染性葡萄膜炎患者从原研英夫利昔单抗转换为英夫利昔单抗-abda 生物类似药后的炎症复发率。
Am J Ophthalmol. 2021 May;225:172-177. doi: 10.1016/j.ajo.2020.08.005. Epub 2020 Aug 12.
6
Evaluating Efficacy, Safety, and Pharmacokinetics After Switching From Infliximab Originator to Biosimilar CT-P13: Experience From a Large Tertiary Referral Center.从英夫利昔单抗原研药转换为生物类似药CT-P13后的疗效、安全性及药代动力学评估:来自大型三级转诊中心的经验
Inflamm Bowel Dis. 2020 Mar 4;26(4):628-634. doi: 10.1093/ibd/izz167.
7
Switching Between Infliximab Originator and Biosimilar in Paediatric Patients with Inflammatory Bowel Disease. Preliminary Observations.炎症性肠病儿科患者中从英夫利昔单抗原研药转换为生物类似药:初步观察
J Crohns Colitis. 2016 Feb;10(2):127-32. doi: 10.1093/ecco-jcc/jjv233. Epub 2015 Dec 30.
8
A Systematic Switch From Originator Infliximab to Biosimilar Infliximab in Patients With Non-Infectious Uveitis.非感染性葡萄膜炎患者从原研英夫利昔单抗到生物类似药英夫利昔单抗的系统性转换。
Am J Ophthalmol. 2021 May;225:178-184. doi: 10.1016/j.ajo.2020.10.013. Epub 2020 Oct 23.
9
Infliximab biosimilar for treating neurosarcoidosis: tolerance and efficacy in a retrospective study including switch from the originator and initiation of treatment.英夫利昔单抗生物类似药治疗神经结节病:一项回顾性研究中的耐受性和疗效,包括从原研药转换和起始治疗。
J Neurol. 2019 May;266(5):1073-1078. doi: 10.1007/s00415-019-09234-y. Epub 2019 Feb 9.
10
Efficacy and tolerability of initiating, or switching to, infliximab biosimilar CT-P13 in inflammatory bowel disease (IBD): a large single-centre experience.英夫利昔单抗生物类似药CT-P13用于炎症性肠病(IBD)起始治疗或换药治疗的疗效及耐受性:一项大型单中心研究经验
Scand J Gastroenterol. 2018 Jun;53(6):700-707. doi: 10.1080/00365521.2018.1464203. Epub 2018 Apr 24.

引用本文的文献

1
Epidemiology, Clinical Data, and Management of Aseptic Abscess Syndrome: Review of Published Cases Outside France.无菌性脓肿综合征的流行病学、临床数据及管理:法国以外已发表病例的综述
Epidemiologia (Basel). 2025 Aug 7;6(3):44. doi: 10.3390/epidemiologia6030044.
2
Intramuscular Aseptic Cyst Syndrome: A Case Report and a Review of the Literature.肌肉内无菌性囊肿综合征:一例报告及文献综述
Cureus. 2025 Jul 14;17(7):e87939. doi: 10.7759/cureus.87939. eCollection 2025 Jul.

本文引用的文献

1
Aseptic abscess associated with SAPHO syndrome: a case report.SAPHO 综合征相关无菌性脓肿:病例报告。
Skeletal Radiol. 2024 Oct;53(10):2307-2313. doi: 10.1007/s00256-023-04493-3. Epub 2023 Oct 27.
2
Aseptic Abscess Syndrome in Rheumatoid Arthritis Patient.类风湿关节炎患者的无菌性脓肿综合征。
Medicina (Kaunas). 2022 Sep 27;58(10):1354. doi: 10.3390/medicina58101354.
3
Aseptic Abscess Syndrome: Clinical Characteristics, Associated Diseases, and up to 30 Years' Evolution Data on a 71-Patient Series.无菌性脓肿综合征:71例患者系列的临床特征、相关疾病及长达30年的演变数据
J Clin Med. 2022 Jun 25;11(13):3669. doi: 10.3390/jcm11133669.
4
Aseptic Abscess Syndrome with Severe Skin Involvement: Case Report.伴有严重皮肤受累的无菌性脓肿综合征:病例报告
Indian J Dermatol. 2020 Sep-Oct;65(5):434-436. doi: 10.4103/ijd.IJD_259_18.
5
Aseptic abscess syndrome.无菌性脓肿综合征。
BMJ Case Rep. 2020 Oct 29;13(10):e236437. doi: 10.1136/bcr-2020-236437.
6
Aseptic Liver Abscesses as an Exceptional Finding in Cogan's Syndrome.无菌性肝脓肿作为科根综合征中的罕见表现
Hepatology. 2021 May;73(5):2067-2070. doi: 10.1002/hep.31547.
7
Successful targeted cytokine blockade in a case of aseptic abscess syndrome.无菌性脓肿综合征病例中成功的靶向细胞因子阻断
J Dtsch Dermatol Ges. 2020 Aug;18(8):908-910. doi: 10.1111/ddg.14147. Epub 2020 Jul 12.
8
TNF-α antagonist infliximab for aseptic abscess syndrome.用于无菌性脓肿综合征的肿瘤坏死因子-α拮抗剂英夫利昔单抗
Presse Med. 2019 Dec;48(12):1579-1580. doi: 10.1016/j.lpm.2019.09.056. Epub 2019 Nov 19.
9
Aseptic Abscess Syndrome, a Case of Prolonged Remission Following Splenectomy.无菌性脓肿综合征,脾切除术后长期缓解一例。
Am J Gastroenterol. 2018 Aug;113(8):1264-1265. doi: 10.1038/s41395-018-0163-z. Epub 2018 Jun 14.
10
Aseptic Abscesses and Inflammatory Bowel Disease: Two Cases and Review of Literature.无菌性脓肿和炎症性肠病:两例病例并文献复习。
Can J Gastroenterol Hepatol. 2017;2017:5124354. doi: 10.1155/2017/5124354. Epub 2017 Feb 6.